Physician profile
Eli M Wolf
NPI 1871178822
$2,749.12
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $1,115 · 2023: $1,047 · 2024: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $432.04 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $397.52 | 2021-2023 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $285.71 | 2022 | |
| Amgen INC. | $174.40 | 2023-2024 | Prolia, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $172.89 | 2023 | Farxiga |
| Novo Nordisk INC | $167.17 | 2023-2024 | Wegovy, Saxenda, Ozempic |
| Radius Health, INC. | $157.08 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $142.87 | 2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.53 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $124.77 | 2023-2024 | Ztlido |
| Teva Pharmaceuticals USA, INC. | $117.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $80.50 | 2023-2024 | |
| Indivior INC. | $77.38 | 2021-2022 | |
| Lilly USA, LLC | $76.89 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.56 | 2023 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $42.51 | 2023-2024 | Nexletol |
| Astellas Pharma US INC | $33.05 | 2024 | Veozah |
| Abbvie INC. | $30.12 | 2023 | |
| Pfizer INC. | $20.85 | 2024 | |
| Coopersurgical, INC. | $19.24 | 2024 | Paragard T 380a |
| Exact Sciences Corporation | $12.74 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.